Welcome to our dedicated page for Pliant Therapeutics SEC filings (Ticker: PLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biopharmaceutical company focused on integrin-based therapeutics. These regulatory documents offer detailed information on the company’s financial condition, clinical development activities, risk factors and corporate governance.
Through periodic reports such as Forms 10-Q and 10-K, Pliant describes research and development spending, progress in programs like bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis, PLN-101095 for solid tumors and PLN-101325 for muscular dystrophies, as well as broader platform efforts in integrin-based drug discovery. Current reports on Form 8-K, including those referenced in the provided data, disclose specific material events such as financial results for a quarter, voluntary prepayment and termination of a loan agreement, changes in executive leadership roles and other significant corporate actions.
Investors can also review filings that discuss strategic realignments of workforce and operations, cash runway considerations and references to risk factors and management’s discussion and analysis sections, which Pliant points to in its press releases. For those tracking equity and governance details, the company’s registration of common stock and related rights on The Nasdaq Stock Market LLC is reflected in its SEC submissions.
On Stock Titan, these filings are available alongside AI-powered summaries that highlight key points, helping readers interpret lengthy documents such as annual and quarterly reports or event-driven 8-Ks. Real-time updates from the SEC’s EDGAR system, combined with structured access to filings related to financial results, material agreements and leadership changes, allow users to follow how Pliant’s disclosures develop over time.
Pliant Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders as a virtual-only event on June 11, 2026 at 8:30 a.m. Pacific Time. Stockholders of record as of April 15, 2026, when 61,914,664 common shares were outstanding, may vote online, by phone, or by mail.
Stockholders will vote on electing three Class III directors for terms running to the 2029 meeting, approving on an advisory basis 2025 compensation for named executive officers, and ratifying Deloitte & Touche LLP as independent registered public accounting firm for 2026. The board also outlines committee structures, director independence, compensation policies, and a pay‑for‑performance executive compensation framework emphasizing variable and equity-based incentives.
Pliant Therapeutics, Inc. Chief Operating Officer Minnie Kuo reported an option repricing affecting her existing stock options. On the April 17, 2026 effective date, she surrendered options covering 150,000, 40,000 and 55,200 shares of common stock with exercise prices of $16.18, $17.44 and $11.14, respectively, and received new options for the same share amounts at an exercise price of $1.33 per share.
The board approved this company‑wide repricing on April 15, 2026 for options granted on or before March 1, 2025, and all other terms, including vesting under the 2020 and 2022 plans, remain unchanged. The repriced awards may revert to their original exercise prices if exercised during an eighteen‑month “Retention Period” starting on the effective date, or if Kuo is terminated for cause or resigns (other than for good reason) before that period ends, subject to the detailed conditions described.
PLIANT THERAPEUTICS, INC. Chief Financial Officer Keith Lamont Cummings reported an option repricing approved by the board on April 17, 2026. Existing stock options granted on or before March 1, 2025 were cancelled and replaced, share-for-share, with new options at an exercise price of $1.33 per share.
The repriced options keep their original vesting schedules and updated expiration dates as previously reported. During a defined Retention Period starting April 17, 2026, any repriced option exercised will revert to its original higher exercise price, and the options can also revert if certain termination or resignation conditions occur.
Pliant Therapeutics President and CEO Bernard Coulie reported an option repricing affecting several existing stock option grants. On the April 17, 2026 effective date, multiple options covering common stock were surrendered to the issuer and regranted with a new exercise price of $1.33 per share, replacing higher original exercise prices such as $34.65 and $26.50. The board approved this repricing for options granted on or before March 1, 2025, with all other terms unchanged.
The repriced options will revert to their original exercise prices if exercised during an eighteen‑month Retention Period starting April 17, 2026, or upon certain termination or resignation events described in the CEO’s severance plan. Several option expiration dates were also corrected, including updates to January 24, 2029 and March 31, 2030.
PLIANT THERAPEUTICS, INC. granted its Chief Human Resource Officer, Lily Cheung, a series of repriced stock options as part of a board-approved option repricing effective April 17, 2026. Existing options covering 123,000, 52,000 and 51,750 shares of common stock, previously struck at $21.935, $17.44 and $11.14 per share, were surrendered back to the company and replaced with new options over the same share amounts at an exercise price of $1.33 per share, the closing price on the effective date.
All other terms of the options, including vesting under the company’s 2020 Stock Option and Incentive Plan, remain unchanged. The repriced options can revert to their original exercise prices if exercised during a defined Retention Period or if Cheung’s employment ends under certain conditions, and a prior expiration date has been corrected to January 19, 2033.
Pliant Therapeutics, Inc. announced that three directors — David E.I. Pyott, Katharine Knobil, M.D., and Suzanne Bruhn, Ph.D. — will retire from the Board and all committees effective at the 2026 Annual Meeting, with each stating the decision was not due to any disagreement with the company.
The Board also approved an option repricing effective April 17, 2026, resetting all employee stock options granted on or before March 1, 2025 under its equity plans to an exercise price of $1.33 per share, the closing market price on the Effective Date. To benefit from the new price, employees must remain in service through a defined Retention Period — 18 months for the executive leadership team and 12 months for other employees — subject to specified exceptions such as certain corporate transactions, qualifying terminations, death or disability. If an employee is terminated for cause, resigns early without good reason (for vice presidents and above), or exercises options before the Retention Period ends, the options revert to their original higher exercise price. The company states the repricing is intended to retain and motivate employees, including executive officers, without additional equity dilution or cash compensation.
Pliant Therapeutics, Inc. has filed a shelf registration to offer up to $300,000,000 of securities, which may include debt securities, common stock, preferred stock, units and warrants. The prospectus also includes an at-the-market offering under a Sales Agreement with Leerink Partners LLC to sell up to $50,000,000 of common stock.
The prospectus describes general terms for future offerings and states proceeds will be used for general corporate purposes, including research and development and clinical programs. The registration incorporates prior SEC filings by reference and notes the company’s common stock trades on Nasdaq under the symbol PLRX (closing price $1.17 on March 27, 2026).
Pliant Therapeutics, Inc. updated its at-the-market stock offering arrangements. The company has a Sales Agreement with Leerink Partners LLC that allows it to offer and sell common stock with an aggregate offering price of up to $50.0 million under an at-the-market prospectus. Effective March 27, 2026, it terminated a prior Controlled Equity Offering℠ Sales Agreement with Cantor Fitzgerald & Co., with no termination penalties and no shares having been sold under the 2021 agreement.